Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737671 · ClinicalTrials.gov registry record · Early Phase 1
Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT01737671: Completed Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01737671 is a Early Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01737671, a Early Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if it is safe to receive methotrexate through the fourth ventricle of the brain in patients with brain tumors. Methotrexate is designed to block cancer cells from dividing, which may slow or stop their growth and spread throughout the body. This may cause the cancer cells to die.
Interventions
- DRUG Leucovorin
- DRUG Methotrexate
- PROCEDURE Ommaya Reservoir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-12-27 |
| Est. Completion | 2018-01-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01737671
The ClinicalTrials.gov registry entry for NCT01737671 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Leucovorin is the first listed.
NCT01737671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01737671 about?
NCT01737671 is a clinical study titled "Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study". The goal of this clinical research study is to learn if it is safe to receive methotrexate through the fourth ventricle of the brain in patients with brain tumors. Methotrexate is designed to block cancer cells from dividing, which may slow or stop their growth and spread throughout the body. This ...
What is the current status of trial NCT01737671?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2012-12-27. Estimated completion is 2018-01-11.
What interventions are being tested in trial NCT01737671?
The interventions under investigation include: Leucovorin (DRUG), Methotrexate (DRUG), Ommaya Reservoir (PROCEDURE).
Who is sponsoring clinical trial NCT01737671?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.